Free tool · No account
Clinical trials for melanoma
Melanoma has been a proving ground for immunotherapy, and many trials build on that. Some are limited to tumors with a BRAF mutation, so that detail is worth including if you have it.
462 recruiting trials. Showing a sample.
- recruitingNANCT06970236
Resistance Exercise in Patients With Ocular Melanoma
Choroidal melanoma (CM) is one of the most common intraocular cancers worldwide. During treatment with episcleral brachytherapy, patients require a week of hospitalization in isolation. The primary aim of this study will be to investigate the effects of resistance training dur...
Listed by the study for Ocular Melanoma. Record updated 2025-05-28.
Sponsored by University of ValenciaFull details on ClinicalTrials.gov → - recruitingPhase 1NCT06910657
IDOV-Immune for Advanced Solid Tumors
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cel...
Listed by the study for Melanoma. Record updated 2026-08-05.
Sponsored by ViroMissile, Inc.Full details on ClinicalTrials.gov → - recruitingNCT06599619
Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi
This study will examine the impact of anti-programmed cell death 1 (PD1) therapy given in the approved adjuvant therapeutic regimens upon the morphologic, histopathologic, molecular and immunologic as well as genomic features of atypical/dysplastic nevi (A/DN) in patients with...
Listed by the study for Melanoma. Record updated 2026-01-26.
Sponsored by John KirkwoodFull details on ClinicalTrials.gov → - recruitingNCT07552467
Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors
This project utilizes LRRC15-specific targeted PET radiotracers to perform PET/MR or PET/CT imaging on healthy volunteers and patients with clinically suspected or confirmed malignancies characterized by high LRRC15 expression-including pancreatic cancer, breast cancer, lung c...
Listed by the study for Melanoma. Record updated 2026-04-27.
Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyFull details on ClinicalTrials.gov → - recruitingPhase 2, Phase 3NCT06624644
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
The goal of this clinical trial is to understand if a new drug called LNS8801 can safely treat patients with melanoma. The primary question to be answered is what is the average length of time during which melanoma does not grow or spread after starting treatment with LNS8801?...
Listed by the study for Melanoma (Skin Cancer). Record updated 2026-04-22.
Sponsored by Linnaeus Therapeutics, Inc.Full details on ClinicalTrials.gov → - recruitingPhase 2NCT04318717
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
This is an open-label, single center, one cohort, non-randomized, phase II study. The aim is to evaluate the efficacy and safety of the combination of hypofractionated radiotherapy (HRT) and pembrolizumab on local tumor control in mucosal melanoma patients. Treatment effect wi...
Listed by the study for Mucosal Melanoma of the Head and Neck. Record updated 2026-08-27.
Sponsored by Washington University School of MedicineFull details on ClinicalTrials.gov → - recruitingPhase 1, Phase 2NCT04752826
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
The goal of this first in human clinical trial is to test BI-1808 administered as single agent and in combination with pembrolizumab in subjects with advanced malignancies whose disease has progressed after standard therapy. The main questions it aims to answer are: * how sa...
Listed by the study for Melanoma. Record updated 2026-09-18.
Sponsored by BioInvent International ABFull details on ClinicalTrials.gov → - recruitingPhase 2NCT04771520
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
This phase II trial studies the effect of avapritinib in treating malignant solid tumors that have a genetic change (mutation) in CKIT or PDGFRA and have spread to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic). Avapritinib may stop th...
Listed by the study for Locally Advanced Melanoma. Record updated 2026-06-11.
Sponsored by M.D. Anderson Cancer CenterFull details on ClinicalTrials.gov → - recruitingNANCT07696715
Timing of Immunotherapy in Melanoma
The TIME-NL trial is a multicenter, randomized, open-label clinical trial in the Netherlands to assess the effect of the timing of the first administration of standard-of-care intravenous combination immunotherapy (early morning versus afternoon) in patients with metastatic me...
Listed by the study for Melanoma. Record updated 2026-08-13.
Sponsored by Radboud University Medical CenterFull details on ClinicalTrials.gov → - recruitingNCT03809585
Observational Study of Iris Tumors
This is an observational study using OCT angiography to assist with tumor characterization in melanotic and amelanotic iris lesions. OCT angiography data from healthy eyes will be compared to eyes with various types of iris tumors.
Listed by the study for Melanoma. Record updated 2025-09-09.
Sponsored by Oregon Health and Science UniversityFull details on ClinicalTrials.gov →
Data from ClinicalTrials.gov, retrieved 2026-10-12. Study sponsors write and update their own records there, including the recruitment status shown here, and the U.S. government does not review or approve every study listed. A trial showing up here is not a recommendation and not a determination that anyone qualifies. Eligibility is decided by the trial's own doctors.
Refine for your situation
Add whatever you know: an age, a city, a mutation from a pathology report. We'll narrow the list to trials that fit. Describe it in your own words.
Trials for other conditions
What we will never do with your records
This generator runs without an account, and KeptWell itself makes the same promises to every family, regardless of plan or price.
- We won't sell your data.
- Not to advertisers, not to data brokers, not to insurers, not to pharma, not to anyone, in any form, ever.
- We won't train AI models on your records.
- KeptWell does not opt in to model training. OpenAI and Anthropic do not use API inputs or outputs to train their models by default.
- We won't lock you in.
- You can export everything in your circle as a ZIP at any time. Cancellation is one click.
Common questions
- Is this melanoma trial finder really free?
- Yes. You describe the situation, we search ClinicalTrials.gov and show what matches. No account, no payment, no email required. Nothing you type is saved.
- Does showing up here mean the patient qualifies?
- No. A listing here is not a recommendation, and the U.S. government does not review or approve every study on ClinicalTrials.gov. These are trials worth asking your care team about. Every trial has detailed eligibility criteria that the trial's own doctors evaluate, and many depend on test results and treatment history that only your medical team knows in full.
- How current is this list?
- The trials come directly from ClinicalTrials.gov and are refreshed daily, with the retrieval date shown under the list. Each study record is written and kept up to date by that study's own sponsor, so the recruitment status is what the sponsor last reported. Each result links to the full, live record, and the finder above always runs a fresh search when you use it.
- What should I do with a trial that looks promising?
- Bring it to your oncologist or care team, and mention the NCT number (the ID that starts with NCT). They can tell you whether it is a genuine fit and refer you to the trial site.
Found trials worth discussing? Keep them next to the records.
The next step is a conversation with the care team, and that goes better when the scans, labs, and trial details live in one place everyone in the family can see. That's what KeptWell is: the binder, but it understands what's inside.
Get started
We'll email you a secure sign-in link. It works whether you're new here or already have an account.